• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Histone Deacetylase Inhibition Protects Mice Against Lethal Postinfluenza Pneumococcal Infection

tetano

Editor, Senior Moderator
Crit Care Med. 2016 Jun 27. [Epub ahead of print]
[h=1]Histone Deacetylase Inhibition Protects Mice Against Lethal Postinfluenza Pneumococcal Infection.[/h] Yagi K[SUP]1[/SUP], Ishii M, Namkoong H, Fujii H, Asami T, Suzuki S, Asakura T, Mizoguchi K, Kamo T, Tasaka S, Iwata S, Kunkel SL, Hasegawa N, Betsuyaku T.
[h=3]Author information[/h]

[h=3]Abstract[/h] [h=4]OBJECTIVES:[/h] Secondary bacterial pneumonia following influenza virus infection is associated with high mortality, but the mechanism is largely unknown. Epigenetic gene regulation appears to play key roles in innate and adaptive immunity. We hypothesized that histone acetylation, a major epigenetic mechanism associated with transcriptionally active chromatin, might contribute to the poor outcome of postinfluenza pneumonia.
[h=4]DESIGN:[/h] Prospective experimental study.
[h=4]SETTING:[/h] University research laboratory.
[h=4]SUBJECTS:[/h] C57BL/6 male mice.
[h=4]INTERVENTIONS:[/h] Mice were infected intranasally with 1.0 ? 10 colony-forming units of Streptococcus pneumoniae, 7 days after intranasal inoculation with five plaque-forming units of influenza virus A/H1N1/PR8/34. The mice were intraperitoneally injected with the histone deacetylase inhibitor trichostatin A (1 mg/kg) or vehicle once a day from 1 hour after pneumococcal infection throughout the course of the experiment. The primary outcome was survival rate.
[h=4]MEASUREMENTS AND MAIN RESULTS:[/h] Trichostatin A significantly suppressed histone deacetylase activity and significantly improved the survival rate of mice (56.3%) after postinfluenza pneumococcal infection when compared with vehicle-treated mice (20.0%), which was associated with a significant decrease in the total cell count of the bronchoalveolar lavage fluid. The interleukin-1β level in the serum and the number of natural killer cells in the lungs were significantly lower in the trichostatin A-treated group.
[h=4]CONCLUSIONS:[/h] The histone deacetylase inhibitor trichostatin A protects mice against postinfluenza pneumonia possibly through multiple factors, including decreasing local cell recruitment into the lungs and suppressing systemic inflammation.


PMID: 27352127 DOI: 10.1097/CCM.0000000000001821
[PubMed - as supplied by publisher]
 
Back
Top Bottom